The health space of the 21st century is a far cry from that of the 70s.
In our time, we have seen a massive wave of innovations in therapeutic options, innovations that improved the quality of life, and extended lifespans. Much of the credit goes to the numerous numbers of medical device startups and university research labs.
On the surface, everything seems to be going well. Tens of billions of dollars are being poured into research and development for health care and medical innovations.
The AJMC website reported that in 2016, the total amount the U.S. spent on medical and health R&D is $17.8 billion. This accumulated amount is from various industry sources including the federal and local government, academic and research institutions, hospital research centers, and grant-giving entities.
The report further stated that the biggest contributor to R&D was industry, which includes biopharmaceutical developers, medical technology developers, and healthcare service companies. Furthermore, at least 7 biopharmaceutical developers contributed over $1 billion each to R&D activities.
Good news, right? But things are not as well as it seems.
The AJMC report also said that while R&D spending is on the rise, growth in that spending has begun to decrease. Between 2015 and 2016, the reported growth was only 6.8%, compared to annual growth of 7.9% between 2013 and 2014 and 8.2% from 2014 to 2015.
The conclusion was that the long-term outlook for R&D is uncertain, saying the long-term outlook for R&D is uncertain, citing administration’s calls for large cuts to federal research funding across non–defense-related areas as a potential cause of reduced spending on health research.
Rick Randall, Principal at Riverhead Advisors, expresses a similar opinion. In our podcast interview, he said the U.S. health space is facing a risk.
According to Rick, “We’ve done wonderful things with technology and the way healthcare is provided. The hot topic for me is how are we going to continue in the U.S. to drive that innovation. How are we going to continue to create a pipeline of innovation? It’s currently at risk.”
“The real risk is, in my view, due to a material change in which the way startup companies or emerging med-tech companies are financed. The venture capital world that I benefited by in the 80s, that’s kind of dried up. Those folks have fled the scene.”
“The life cycle of a healthcare company back then was four years. Now that the gestation period of a company to exit is more about 10 to 15 years. That’s caused a lot of the venture folks to flee.”
“I’m a little concerned that we’re going to see a slowdown of innovation, which really doesn’t benefit anyone.”
Rick further explained that it is an issue of stack risks, a phrase he borrowed from a venture capitalist who explained it to him about a decade ago. He said that when he first became the CEO, there were only two things to worry about, and it’s whether the device will work on real live human beings, and to get the FDA to clear the device for commercial use.
He said “Today they’re stacked risks, and it’s taking longer to prove out each one of these risks set. So, is the concept going to work? Where am I going to learn we can work in human beings? So, there is a process you must go through to even get into the most lenient countries to test the device. Then the FDA risk. Is it going to require a full clinical study or a 510 Caywood clinical or straight up 5 10? And then when you get through all that which is typically years five or six, then can you get the device reimbursed?”
“I think it’s that additional stacked risk of reimbursement in our healthcare system that has kind of caused the venture capitalist to finally give up, raise their hands, and move on to dotcom or technology plays.”
“But these stacked risks now have gobbled up the better part of a decade of development. And more importantly, exhausted some of the funds that used to be available to us in the health care in the med-tech sector.”
I wonder. Is there more to it than just the lack of financial support and venture capitalists?
Duke Rohlen, CEO at Ajax Health Inc. and EPIX Therapeutics, has another theory.
In our interview, he stated, “For me, the most pressing issue facing all healthcare is how you take out cost, you dramatically reduce cost in the healthcare system. The cost of new care, inventions, new technologies are actually reducing the profitability of our healthcare system as opposed to making it more viable, affordable.”
Now that our country’s healthcare system is battered with so many issues ranging from a clamor for a more efficient and patient-friendly healthcare system to rising healthcare costs and the possibility of lacking healthcare providers in the coming years, what are we doing to continue the stream of innovations?
For Duke Rohlen, the gentleman distinguished in his ability to create companies to add value in the healthcare space and also to create viable business models that can get acquired, the answer is to lower the cost and reduce the expenses of innovations.
This means focusing on the critical pieces of technology – speed, efficacy, simplicity, and cost. It must be all four at the same time, not just one or two out of four. Currently, AJAX Health and Epix Therapeutics are in the process of getting FDA approval for one of their most recent innovations.
Scott Phillips, founder, and CEO of Starfish Medical discovered that connectivity is the key to continuing innovations in medical devices. For him, implementing device connectivity in hospitals or health facilities can make a significant difference in the care provided to patients.
For Mike Kijewski, CEO at MedCrypt, the focus should be on ensuring that companies and teams building healthcare technologies can rely on a software or hardware product that will not be vulnerable to cybersecurity issues.
We can see that technology plays a significant role in health care innovation.
For each of these stakeholders, they discovered opportunities where they merged technology and medical innovations. Advances in medical devices will always be challenging, but we have can look forward to amazing new possibilities and opportunities.
Effective communication is an integral part of any relationship or organization, but it is even more significant...Read More
Part of the ongoing conversation in improving healthcare is the importance of patients’ adherence to prescriptions. We all...Read More
Despite technological advances that have brought the best diagnostic tools, advanced treatments, and cutting-edge equipment in medicine,...Read More
Andrew Botham Chief Scientific Officer at
Chris Hermann Founder and CEO at
Clean Hands - Safe Hands